After co-treatment with MWCNTs and PbAc, we detected that both the two AMPK activators (PF-06409577 and A-769662) could significantly reverse the PPARγ expression levels in primary hepatocytes from NAFLD mice (Figure 9E, 9F). Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.